New combo therapy shows promise for rare gut tumors

NCT ID NCT04750954

First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 37 times

Summary

This early-stage trial tests a new drug (peposertib) combined with a radioactive therapy (lutetium 177 dotatate) for people with a type of neuroendocrine tumor in the gut or pancreas. The goal is to find the best dose and see if the combo is safe and works better than the radioactive therapy alone. About 29 adults with tumors that show up on a special scan will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah, 84112, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky, 40536, United States

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida, 33136, United States

Conditions

Explore the condition pages connected to this study.